OptiNose
OPTN
OPTN was delisted on the 20th of May, 2025.
72 hedge funds and large institutions have $543M invested in OptiNose in 2018 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 36 increasing their positions, 4 reducing their positions, and 5 closing their positions.
800% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 4
460% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 5
143% more capital invested
Capital invested by funds: $223M → $543M (+$320M)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
47% more funds holding
Funds holding: 49 → 72 (+23)
1.17% more ownership
Funds ownership: 1.98% → 3.16% (+1.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$30.3M |
| 2 |
BlackRock
New York
|
+$17.3M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$13.6M |
| 4 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
+$13.1M |
| 5 |
TA
Tamarack Advisers
Carlsbad,
California
|
+$12.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$6.69M |
| 2 |
PCM
Peregrine Capital Management
Minneapolis,
Minnesota
|
-$6.36M |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$1.5M |
| 4 |
IBT
International Biotechnology Trust
London,
United Kingdom
|
-$1.3M |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$538K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
OAM
76
Oxford Asset Management
Oxford,
United Kingdom
| – | -$1.5M | -4,988 | Closed |
|
|
IBT
77
International Biotechnology Trust
London,
United Kingdom
| – | -$1.3M | -4,333 | Closed |
|
|
78
Macquarie Group
Sydney, NSW 2000,
Australia
| – | -$538K | -1,790 | Closed |
|
OPTN Hedge Fund Activity: Q2 2018 in Review
72 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in OptiNose (OPTN) for Q2 2018, worth a combined $543M — up 143% from $223M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new OPTN positions and 5 closed out — a net gain of 23 holders — while 36 added to existing stakes and 4 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $30.3M. The largest seller was PFM Health Sciences, exiting entirely with an estimated $6.69M sold.
- 72 institutional investors held OptiNose (OPTN) as of Q2 2018, up from 49 in Q1 2018.
- Funds reported $543M of OptiNose stock for Q2 2018, up 143% quarter-over-quarter.
- 28 funds opened new OptiNose positions in Q2 2018 and 5 closed out, a net change of +23 holders.
- The largest OptiNose buyer in Q2 2018 was JP Morgan Chase, an estimated $30.3M added.
- The largest OptiNose seller in Q2 2018 was PFM Health Sciences, an estimated $6.69M sold.
Based on aggregated 13F filings for Q2 2018.